Company Valuation: Biosynex

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 151.6 289.9 141 85.85 18.51 11.17
Change - 91.16% -51.35% -39.13% -78.44% -39.63%
Enterprise Value (EV) 1 130.6 193.2 105.9 125.7 71.44 64.36
Change - 47.93% -45.16% 18.6% -43.14% -9.91%
P/E 5.44x 2.63x 9.08x -2.42x -0.43x -0.19x
PBR 2.29x 1.62x 0.87x 0.72x 0.23x 0.3x
PEG - 0x -0.1x 0x -0x 0x
Capitalization / Revenue 0.99x 0.76x 0.72x 0.92x 0.18x 0.12x
EV / Revenue 0.85x 0.5x 0.54x 1.35x 0.71x 0.68x
EV / EBITDA 2.84x 1.36x 2.28x -4.21x -3.22x -4.72x
EV / EBIT 2.86x 1.37x 2.72x -3.48x -2.59x -2.47x
EV / FCF 7.61x 2.62x -3.59x -2.83x -43.6x 4.54x
FCF Yield 13.1% 38.1% -27.9% -35.3% -2.29% 22%
Dividend per Share 2 0.2 2 - - - -
Rate of return 1.2% 7.6% - - - -
EPS 2 3.05 10.01 1.52 -3.45 -4.03 -3.159
Distribution rate 6.56% 20% - - - -
Net sales 1 153.9 382.5 196.6 92.98 101.2 95.19
EBITDA 1 46.02 141.8 46.49 -29.82 -22.16 -13.64
EBIT 1 45.73 140.7 38.88 -36.15 -27.53 -26.05
Net income 1 31.37 104 15.66 -36.95 -43.33 -58.22
Net Debt 1 -21.07 -96.72 -35.09 39.8 52.94 53.19
Reference price 2 16.6000 26.3200 13.8000 8.3500 1.7200 0.5960
Nbr of stocks (in thousands) 9,135 11,014 10,220 10,281 10,761 18,748
Announcement Date 21/4/21 25/4/22 28/4/23 30/4/24 30/4/25 7/5/26
1EUR in Million2EUR
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 19.98M
-50.34x16.45x-120.47x-.--% 21.7B
17.78x1.97x8.34x1.44% 9.9B
-77.94x11.41x-104.43x-.--% 7.56B
20.06x4.25x11.73x - 6.59B
158.14x5.54x31.15x-.--% 6.11B
21.84x7.57x17.01x2.63% 6B
21.57x3.56x11.04x1.75% 4.27B
16.56x - - 3.88% 2.79B
Average 15.96x 7.25x -20.80x 1.39% 7.21B
Weighted average by Cap. -2.11x 9.42x -46.74x 0.83%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA